alphaIIbbeta3 interaction with
fibrinogen promotes Src-dependent platelet spreading in vitro. To determine the consequences of this outside-in signaling pathway in vivo, a "beta3(Delta760-762)" knockin mouse was generated that lacked the 3 C-terminal beta3 residues (
arginine-
glycine-
threonine [RGT]) necessary for alphaIIbbeta3 interaction with c-Src, but retained beta3 residues necessary for
talin-dependent
fibrinogen binding. beta3(Delta760-762) mice were compared with wild-type beta3(+/+) littermates, beta3(+/-) heterozygotes, and knockin mice where beta3 RGT was replaced by beta1 C-terminal
cysteine-
glycine-
lysine (EGK) to potentially enable signaling by
Src kinases other than c-Src. Whereas beta3(+/+), beta3(+/-) and beta3/beta1(EGK) platelets spread and underwent
tyrosine phosphorylation normally on
fibrinogen, beta3(Delta760-762) platelets spread poorly and exhibited reduced
tyrosine phosphorylation of c-Src substrates, including beta3 (Tyr(747)). Unlike control mice, beta3(Delta760-762) mice were protected from
carotid artery thrombosis after vessel injury with
FeCl(3). Some beta3(Delta760-762) mice exhibited prolonged tail bleeding times; however, none demonstrated spontaneous
bleeding, excess
bleeding after surgery, fecal blood loss, or
anemia.
Fibrinogen binding to beta3(Delta760-762) platelets was normal in response to saturating concentrations of
protease-activated receptor 4 or
glycoprotein VI agonists, but responses to
adenosine diphosphate were impaired. Thus, deletion of beta3 RGT disrupts c-Src-mediated alphaIIbbeta3 signaling and confers protection from arterial
thrombosis. Consequently, targeting alphaIIbbeta3 signaling may represent a feasible antithrombotic strategy.